欧州連合 - リトアニア語 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psoriazė - imunosupresantai - treatment of moderate-to-severe plaque psoriasis in adults.

リトアニア - リトアニア語 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - ranolazinas - pailginto atpalaidavimo tabletės - 375 mg - ranolazine

リトアニア - リトアニア語 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - ranolazinas - pailginto atpalaidavimo tabletės - 500 mg - ranolazine

リトアニア - リトアニア語 - SMCA (Valstybinė vaistų kontrolės tarnyba)

krka, d.d., novo mesto - ranolazinas - pailginto atpalaidavimo tabletės - 750 mg - ranolazine

欧州連合 - リトアニア語 - EMA (European Medicines Agency)

samsung bioepis nl b.v. - eculizumab - hemoglobinurija, paroksizminis - imunosupresantai - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

リトアニア - リトアニア語 - SMCA (Valstybinė vaistų kontrolės tarnyba)

phagecon - serviços e consultoria farmacêutica lda. - etofenamatas - gelis - 100 mg/g - etofenamate

欧州連合 - リトアニア語 - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - prostatos navikai - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

欧州連合 - リトアニア語 - EMA (European Medicines Agency)

extrovis eu ltd. - lakozamidas - epilepsija - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

欧州連合 - リトアニア語 - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - daugybinė mieloma - antinavikiniai vaistai - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

リトアニア - リトアニア語 - SMCA (Valstybinė vaistų kontrolės tarnyba)

sumar pharma ehf - desmopresinas - poliežuvinės tabletės - 120 µg - desmopressin